Vagus nerve stimulation as a treatment for refractory epilepsy

A 15-year experience in an Italian Tertiary - Care epilepsy center

Chiara Pizzanelli, Renato Galli, Filippo S. Giorgi, Alfonso Iudice, Enrica Bonanni, Veronica Pelliccia, Stella Jensen, Laura Manca, Bruno Lenzi, Ludovico Lutzemberger, Giuliano Parenti, Francesco Fornai, Luigi Murri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients. Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1). Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group). Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalLetters in Drug Design and Discovery
Volume8
Issue number4
Publication statusPublished - May 2011

Fingerprint

Vagus Nerve Stimulation
Tertiary Care Centers
Epilepsy
Therapeutics
Generalized Epilepsy
Temporal Lobe Epilepsy
Seizures
Biomarkers

Keywords

  • Alternative therapy
  • Epilepsy
  • Long-term study
  • Neurosurgery
  • Pharmacoresistance
  • Vagus nerve stimulation

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

Cite this

Pizzanelli, C., Galli, R., Giorgi, F. S., Iudice, A., Bonanni, E., Pelliccia, V., ... Murri, L. (2011). Vagus nerve stimulation as a treatment for refractory epilepsy: A 15-year experience in an Italian Tertiary - Care epilepsy center. Letters in Drug Design and Discovery, 8(4), 321-329.

Vagus nerve stimulation as a treatment for refractory epilepsy : A 15-year experience in an Italian Tertiary - Care epilepsy center. / Pizzanelli, Chiara; Galli, Renato; Giorgi, Filippo S.; Iudice, Alfonso; Bonanni, Enrica; Pelliccia, Veronica; Jensen, Stella; Manca, Laura; Lenzi, Bruno; Lutzemberger, Ludovico; Parenti, Giuliano; Fornai, Francesco; Murri, Luigi.

In: Letters in Drug Design and Discovery, Vol. 8, No. 4, 05.2011, p. 321-329.

Research output: Contribution to journalArticle

Pizzanelli, C, Galli, R, Giorgi, FS, Iudice, A, Bonanni, E, Pelliccia, V, Jensen, S, Manca, L, Lenzi, B, Lutzemberger, L, Parenti, G, Fornai, F & Murri, L 2011, 'Vagus nerve stimulation as a treatment for refractory epilepsy: A 15-year experience in an Italian Tertiary - Care epilepsy center', Letters in Drug Design and Discovery, vol. 8, no. 4, pp. 321-329.
Pizzanelli, Chiara ; Galli, Renato ; Giorgi, Filippo S. ; Iudice, Alfonso ; Bonanni, Enrica ; Pelliccia, Veronica ; Jensen, Stella ; Manca, Laura ; Lenzi, Bruno ; Lutzemberger, Ludovico ; Parenti, Giuliano ; Fornai, Francesco ; Murri, Luigi. / Vagus nerve stimulation as a treatment for refractory epilepsy : A 15-year experience in an Italian Tertiary - Care epilepsy center. In: Letters in Drug Design and Discovery. 2011 ; Vol. 8, No. 4. pp. 321-329.
@article{8cd9416d1c7e4c32b35274f4c576dcc8,
title = "Vagus nerve stimulation as a treatment for refractory epilepsy: A 15-year experience in an Italian Tertiary - Care epilepsy center",
abstract = "Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients. Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1). Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9{\%} after 1 year, 40.3±4.6{\%} after 2 years, 48.0±5.4{\%} after 3 years, 53.4±7.9{\%} after 5 years and 48.1{\%}±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group). Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.",
keywords = "Alternative therapy, Epilepsy, Long-term study, Neurosurgery, Pharmacoresistance, Vagus nerve stimulation",
author = "Chiara Pizzanelli and Renato Galli and Giorgi, {Filippo S.} and Alfonso Iudice and Enrica Bonanni and Veronica Pelliccia and Stella Jensen and Laura Manca and Bruno Lenzi and Ludovico Lutzemberger and Giuliano Parenti and Francesco Fornai and Luigi Murri",
year = "2011",
month = "5",
language = "English",
volume = "8",
pages = "321--329",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Vagus nerve stimulation as a treatment for refractory epilepsy

T2 - A 15-year experience in an Italian Tertiary - Care epilepsy center

AU - Pizzanelli, Chiara

AU - Galli, Renato

AU - Giorgi, Filippo S.

AU - Iudice, Alfonso

AU - Bonanni, Enrica

AU - Pelliccia, Veronica

AU - Jensen, Stella

AU - Manca, Laura

AU - Lenzi, Bruno

AU - Lutzemberger, Ludovico

AU - Parenti, Giuliano

AU - Fornai, Francesco

AU - Murri, Luigi

PY - 2011/5

Y1 - 2011/5

N2 - Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients. Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1). Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group). Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.

AB - Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients. Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1). Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group). Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.

KW - Alternative therapy

KW - Epilepsy

KW - Long-term study

KW - Neurosurgery

KW - Pharmacoresistance

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=79955948523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955948523&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 321

EP - 329

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 4

ER -